REYON Pharmaceutical (representative directors Sunok Jeong and Yonghwan Yoo), together with GNP Bioscience  (representative directors Seonghyeon Ho and Sujin Park) and KNOTUS (representative directors Inseong Jeong and Dohyeong Kim), has identified a new candidate for the treatment of COVID-19.

REYON Pharmaceutical has been focused on securing the effectiveness of new substances through its own synthesis as candidates for various antiviral drugs together with GNP Bioscience and the joint research team of Notus. It was revealed on the 27th that as a result of examining the applicability of COVID-19 to one of the new candidates, the companies have produced very positive results that inhibit the proliferation of the virus and induce early recovery.
Based on this, the joint research team is conducting research to increase the bioavailability and stability of new candidate substances to develop treatments for COVID-19 and related viral infections. It plans to complete non-clinical development as soon as possible and commence clinical trials as soon as possible.

Representative director of REYON Pharmaceutical, Yonghwan Yoo said, "COVID-19 is causing a very painful and difficult situation not only in Korea but also around the world.” "Based on the synergy through joint research of the three companies, by securing substances that show the potential to cure COVID-19, which is a recent social issue, we have laid the groundwork for contributing to protecting human health and life from the threat of novel viruses.” He concluded by saying, "Due to the nature of drug development, there are many steps to be taken in the future, but REYON Pharmaceutical will continue to put its best foot forward based on solid collaboration with our partners in the future.”

Meanwhile, REYON Pharmaceutical is continuously expanding its business areas in the chemical and bio fields based on its synthesis and fermentation technology, while GNP Bioscience is in the process of conducting joint research and development of natural pharmaceuticals and biopharmaceuticals with REYON Pharmaceutical. Also, KNOTUS was established in 2012 and is listed on KOSDAQ as the number one non-clinical CRO company in Korea.